Novel pharmaceutical
A combination of ivermectin and molnupiravir provides an effective oral and inhalable treatment for COVID-19, addressing the need for easy administration and enhanced antiviral action against SARS-CoV-2 infection.
Patent Information
- Application Number
- JP2021171116
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2021-10-19
- Publication Date
- 2024-12-11
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a need for effective preventive and therapeutic agents for COVID-19, particularly for mild and moderate cases, as existing treatments are limited and often require hospital visits.
A combination drug comprising ivermectin and molnupiravir, administered orally or via inhalation, to suppress SARS-CoV-2 infection and treat COVID-19, leveraging their distinct antiviral mechanisms for enhanced efficacy.
The combination of ivermectin and molnupiravir effectively suppresses SARS-CoV-2 infection and alleviates COVID-19 symptoms, offering easy administration without hospital visits and potentially enhanced antiviral action.
Smart Images

Figure 2024170686000001
Abstract
Description
[Technical field]
[0001] The present invention relates to a preventive and / or therapeutic drug for diseases caused by SARS-CoV-2 infection. [Background technology]
[0002] COVID-19 (Japanese name: novel coronavirus infection) is an infectious disease caused by the 2019 novel coronavirus (SARS-CoV-2). COVID-19 was confirmed to have occurred in Wuhan, People's Republic of China in November 2019 and reported to the WHO in December of the same year, and has since spread worldwide. Symptoms include fever, dry cough, fatigue, phlegm, shortness of breath, sore throat, headache, muscle pain, joint pain, abnormal smell, and abnormal taste, and in severe cases, pneumonia worsens, leading to respiratory failure and death. There are still many unknowns about the virus, such as its infectiousness and the rate at which it becomes severe when contracted. In addition, because it is a new type of virus, effective treatments are still being sought, causing anxiety around the world.
[0003] To date, many existing drugs have been screened, and ivermectin is expected to be a treatment for COVID-19, a disease caused by SARS-CoV-2 infection (Non-Patent Document 1). Molnupiravir is known to exert an antiviral effect by causing replication errors during viral RNA replication, and is expected to be a treatment for COVID-19, a disease caused by SARS-CoV-2 infection (Non-Patent Document 2). [Prior art documents] [Non-patent literature]
[0004] [Non-Patent Document 1] https: / / www.sciencedirect.com / science / article / pii / S0166354220302011 [Non-Patent Document 2] Translational Research 218: 16-28. (April 2020). Summary of the Invention [Problem to be solved by the invention]
[0005] The present invention aims to provide a new medicament for preventing and / or treating COVID-19, a disease caused by SARS-CoV-2 infection, in particular, for preventing and / or treating mild or moderate COVID-19. [Means for solving the problem]
[0006] Ivermectin tablets are already being used in Japan as a treatment for intestinal strongyloidiasis and scabies, but because it has antiviral activity, it is also expected to be an orally administered drug for the prevention and / or treatment of COVID-19, a disease caused by SARS-CoV-2 infection. In addition, Molnupiravir exhibits antiviral activity and is therefore expected to be an orally administered treatment for COVID-19, a disease caused by SARS-CoV-2 infection. Therefore, the inventors focused on combining ivermectin and molnupiravir to suppress infection by SARS-CoV-2 or to prevent and / or treat COVID-19, and arrived at the present invention.
[0007] That is, the present invention provides the following inventions [1] to [3]. [1] A medicine comprising a combination of ivermectin and molnupiravir. [2] A preventive and / or therapeutic drug for SARS-CoV-2 infection comprising a combination of ivermectin and molnupiravir. [3] A preventive and / or therapeutic drug for COVID-19 comprising a combination of ivermectin and molnupiravir. Effect of the Invention
[0008] The pharmaceutical composition of the present invention, which is a combination of ivermectin and molnupiravir, is effective in suppressing infection with SARS-CoV-2 or preventing and / or treating COVID-19, i.e., improving or eliminating the symptoms of COVID-19 (fever, cough, shortness of breath, muscle pain, runny nose, sore throat, headache, nausea, vomiting, abdominal pain, diarrhea, dysosmia, and dysgeusia). In addition, both ivermectin and molnupiravir are drugs that are effective when administered orally, and unlike previously known injectables such as remdesivir, casirivimab, imdevimab, and sotrovimab, they are easy to administer, so they can be prescribed and administered not only in hospitals but also in ordinary clinics. In addition, since the mechanism of the antiviral action of ivermectin is different from that of molnupiravir, it is expected that the antiviral action will be enhanced by using them together. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0009] The medicine of the present invention comprising a combination of ivermectin and molnupiravir is effective in suppressing SARS-CoV-2 infection or preventing and / or treating COVID-19.
[0010] The ivermectin used in the present invention is at least ivermectin B 1a or ivermectin B 1b It is sufficient to include either Ivermectin B 1a and Ivermectin B 1b A mixture containing both of these is preferred, and ivermectin B 1a More than 90% of Ivermectin B 1b Mixtures containing less than 10% are more preferred.
[0011] In the present invention, ivermectin is a known chemical substance and can be obtained by purchasing a commercial product or by producing it by a method such as selective catalytic hydrogenation of avermectin followed by removal of the catalyst.
[0012] The route of administration of the ivermectin-containing medicine of the present invention is not particularly limited, and may be oral or parenteral. When a medicine containing ivermectin is orally administered, the dosage varies depending on the patient's weight, age, sex, symptoms, etc., but generally, for an adult, the dosage is 0.1 to 1 mg / kg body weight per day as ivermectin, preferably 0.15 to 0.5 mg / kg body weight, and more preferably 0.2 to 0.4 mg / kg body weight. If the body weight of an adult is 60 kg, the daily dosage is generally 6 to 60 mg, and preferably 12 to 24 mg. The daily dosage can be administered in divided doses about 1 to 4 times.
[0013] Examples of oral preparations include capsules, pills, granules, fine granules, powders, tablets, liquids, syrups, jellies, and lozenges, and these oral preparations containing ivermectin can be produced by known methods. As the dosage form of oral preparations, solid preparations are preferred, and among them, capsules, pills, granules, fine granules, powders, and tablets are preferred. The ivermectin content per dosage unit of these oral preparations is preferably 3 mg and 6 mg, taking into consideration the dosage amount. In Japan, tablets containing 3 mg of ivermectin are available on the market, and if ivermectin is approved for the suppression of SARS-CoV-2 infection or the prevention and / or treatment of COVID-19, it may be possible to use these tablets.
[0014] In the present invention, molnupiravir is a known chemical substance whose IUPAC name is ((2R,3S,4R,5R)-3,4-dihydroxy-5-(4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate, and can be obtained by purchasing a commercially available product or by producing it by a known method, etc.
[0015] The route of administration of the molnupiravir-containing medicine of the present invention is not particularly limited, and may be oral or parenteral. When a medicine containing molnupiravir is orally administered, the dosage varies depending on the patient's weight, age, sex, symptoms, etc., but the daily dosage of molnupiravir for an adult is usually 10 to 5000 mg, preferably 100 to 3200 mg, and more preferably 200 to 1600 mg. The daily dosage can be administered in divided doses about 1 to 4 times.
[0016] Examples of oral preparations include capsules, pills, granules, fine granules, powders, tablets, liquids, syrups, jellies, lozenges, etc., and these oral preparations containing molnupiravir can be produced by known methods. As the dosage form of oral preparations, solid preparations are preferred, and among them, capsules, pills, granules, fine granules, powders, and tablets are preferred. The molnupiravir content per dosage unit of these oral dosage formulations is preferably 100 mg and 200 mg, taking into consideration the dosage amount.
[0017] Since the ivermectin and molnupiravir used in the present invention each have antiviral effects, dosage forms such as inhalants that can be applied directly to the lower respiratory tract, which is the site of infection by SARS-CoV-2, are easy to administer, unlike injections, and can be considered a preferred dosage form for parenteral administration. In order to apply ivermectin and molnupiravir to the lower respiratory tract (trachea, bronchi, lungs), from the viewpoint of the reach of ivermectin and molnupiravir to the lower respiratory tract, the particle size is preferably 0.5 to 10 μm, more preferably 0.5 to 8 μm, and even more preferably 0.5 to 6 μm. Specifically, the aerodynamic mass median diameter of ivermectin and molnupiravir is preferably 0.5 to 10 μm, more preferably 0.5 to 8 μm, and even more preferably 0.5 to 6 μm, respectively. Here, the particle size of ivermectin and molnupiravir is the particle size of the ivermectin-containing powder or molnupiravir-containing powder in the case of a powder, and is the particle size of the ivermectin-containing spray droplets or and molnupiravir-containing spray droplets in the case of a liquid preparation. In the case of a powder, this particle size can be adjusted by pulverization, sieving, etc. during powder production. In the case of sprayed droplets, the amount may be appropriately adjusted depending on the type of nebulizer (jet type, ultrasonic type, mesh type, etc.) used when inhaling the liquid preparation.
[0018] The form of the inhalant may be, but is not limited to, an inhalable powder, an inhalable liquid, or an inhalable aerosol. When using an inhalant of ivermectin or molnupiravir, an appropriate tool or device for inhalation administration may be used, or the inhalant may be filled into a container that also functions as an inhalation tool.
[0019] The powdered inhalation preparation is a formulation to be inhaled as an aerosol of ivermectin-containing powder or molnupiravir-containing powder prepared so that the inhalation amount is constant. The ivermectin-containing powder or molnupiravir-containing powder may be prepared as a powder having a particle size of preferably 0.5 to 10 μm, more preferably 0.5 to 8 μm, and even more preferably 0.5 to 6 μm, respectively; specifically, the powder may be prepared as a powder having a mass median aerodynamic diameter of preferably 0.5 to 10 μm, more preferably 0.5 to 8 μm, and even more preferably 0.5 to 6 μm.
[0020] Sugars or sugar alcohols can also be used as additives in the ivermectin-containing powder or molnupiravir-containing powder. Examples of sugars include lactose hydrate, sucrose, and glucose, and examples of sugar alcohols include erythritol, isomalt, lactitol, maltitol, mannitol, sorbitol, and xylitol. In addition, examples of the ivermectin-containing powder include a freeze-dried product containing ivermectin and a lactic acid / glycolic acid copolymer as described in JP 2019-69906 A.
[0021] A specific example of the powdered inhalation agent is a dry powder inhaler (hereinafter, abbreviated as DPI). The device used for the powdered inhalation agent of the present invention can be one that is usually used as a DPI. For example, devices using capsules include Monohaler, Handihaler, Breezhaler, Flowcaps, etc. Also included are Diskhaler, Diskus, Ellipta, etc., which use aluminum blisters. Examples of reservoir-type devices in which a container is filled with powder include Turbuhaler, Clickhaler, Swinghaler, and Twisthaler.
[0022] Inhalation liquids are liquid inhalation preparations that are inhaled using a nebulizer or the like. Ivermectin or molnupiravir may be dissolved or suspended in an appropriate solvent to prepare a solution or suspension. During preparation, isotonicity agents, pH adjusters, etc. may be added. The droplets of the inhalation liquid may be adjusted to preferably 0.5 to 10 μm, more preferably 0.5 to 8 μm, and even more preferably 0.5 to 6 μm, depending on the type of nebulizer (jet type, ultrasonic type, mesh type, etc.); specifically, the mass median aerodynamic diameter may be adjusted to preferably 0.5 to 10 μm, more preferably 0.5 to 8 μm, and even more preferably 0.5 to 6 μm. The device used for the inhalation liquid of the present invention can be a nebulizer that is usually used, such as a type that atomizes the liquid medicine with compressed air (jet type), a type that atomizes the liquid medicine using the vibration of an ultrasonic vibrator (jet type), or a type that atomizes the liquid medicine by pushing it through mesh holes by vibration or the like (mesh type).
[0023] The inhalation aerosol is a metered dose inhalation formulation that can spray a fixed amount of ivermectin or molnupiravir together with a propellant filled in a container. The droplets sprayed by the inhalation aerosol can be adjusted to preferably 0.5 to 10 μm, more preferably 0.5 to 8 μm, and even more preferably 0.5 to 6 μm, by adjusting the composition of the solution or suspension of ivermectin (including a lyophilized product containing ivermectin and poly(lactic acid / glycolic acid)) or molnupiravir, the propellant to be filled, the nozzle shape which is a component of the container, and the like; specifically, the mass median aerodynamic diameter can be adjusted to preferably 0.5 to 10 μm, more preferably 0.5 to 8 μm, and even more preferably 0.5 to 6 μm. Inhalation aerosols can be manufactured by dissolving or suspending ivermectin (a lyophilized product containing ivermectin and poly(lactic acid-co-glycolic acid)) or molnupiravir in an appropriate solvent to prepare a solution or suspension, filling it together with a liquid propellant into a pressure-resistant container, and attaching a metered-dose valve. Dispersants, stabilizers, etc. can be added when preparing the solution or suspension. A specific example of the inhalation aerosol agent is a pressurized metered dose inhaler.
[0024] The medicine of the present invention, which is a combination of ivermectin and molnupiravir, can be administered simultaneously or at different times, and when administered simultaneously, ivermectin and molnupiravir can be formulated in separate dosage forms or in the same dosage form. Also, ivermectin and molnupiravir can be formulated together to form a so-called combination drug. When ivermectin and molnupiravir are formulated in the same dosage form, or when a combination drug containing ivermectin and molnupiravir is prepared, it is preferable to use the oral administration formulation or inhalation agent as described above. Furthermore, even in these formulations and combination drugs with the same dosage form, it is preferable to use the dosage as described above.
[0025] In the pharmaceutical of the present invention, both ivermectin and molnupiravir have antiviral and viral proliferation inhibitory effects, but their mechanisms of action are different from each other. Therefore, it is expected that the antiviral effects will be enhanced by using them in combination. In addition, since the effect of the pharmaceutical of the present invention is to inhibit viral proliferation, it is desirable to administer it early after SARS-CoV-2 infection is confirmed. EXAMPLES
[0026] The present invention will be specifically described below with reference to examples, but the present invention is not limited to these examples in any way.
[0027] Reference example 1 Ivermectin was pulverized in a jet mill to obtain a pulverized product. The average particle size D50 of the pulverized product was 2.0 μm. The pulverized product and lactose hydrate were mixed with lactose hydrate so that the concentration of ivermectin was 10%, to obtain an inhalation powder. The formulation is shown in Table 1. In addition, 0.03 g of the obtained powder was filled into a capsule to produce an inhalation powder-filled capsule.
[0028] Control Example 1 Unground ivermectin and lactose hydrate were mixed with lactose hydrate so that the ivermectin concentration was 10%, to obtain a powder inhalation formulation. The formulation is shown in Table 1. 0.03 g of the obtained powder was filled into a capsule to produce a powder inhalation capsule.
[0029] Test Example 1 For the dry powder inhalants obtained in Reference Example 1 and Control Example 1, the fine particle load (FPF) (%) and mass median aerodynamic diameter were measured to evaluate the aerodynamic properties using an inhalation device. The fine particle load (FPF) (%) and mass median aerodynamic diameter were evaluated using Apparatus 1, a multi-stage liquid impinger, in accordance with the aerodynamic particle size measurement method for inhalants in the Japanese Pharmacopoeia, Seventeenth Edition, First Supplement. As a result, the powder inhalation formulation of Reference Example 1, which used crushed ivermectin, had a fine particle dose (FPF) (%) of 29.9% and a mass median aerodynamic diameter of 2.8 μm, suggesting that it is possible for ivermectin to reach the deep lungs. The powder inhalation formulation of Control Example 1, which used uncrushed ivermectin, had a fine particle dose (FPF) (%) of 3.5% and a mass median aerodynamic diameter of more than 10 μm, suggesting that it is difficult for ivermectin to reach the deep lungs.
[0030] [Table 1]
[0031] Reference example 2 Ivermectin was dissolved in ethyl alcohol, and a phosphate buffer and water were added to prepare an inhalation solution so that the final concentration of ivermectin was 0.5%.
[0032] Test Example 2 The inhalation liquid preparation obtained in Reference Example 2 was visually confirmed to be sprayed as a mist using a nebulizer as a device. The mist-formed medicine was then sampled and the particle size was confirmed under a microscope. It was confirmed that the liquid preparation in Reference Example 2 was sprayed as a mist, with a particle size of 2 to 6 μm. Therefore, it was determined that the medicinal liquid of Reference Example 2 was suitable as an inhalation liquid.
[0033] Example 1 When a combination treatment of administering tablets containing ivermectin and capsules containing molnupiravir to patients infected with SARS-CoV-2 and with mild COVID-19 was attempted, the symptoms of COVID-19 (fever, cough, shortness of breath, muscle pain, runny nose, sore throat, headache, nausea, vomiting, abdominal pain, diarrhea, and abnormal smell and taste) improved or disappeared.
Claims
1. A medicine comprising a combination of ivermectin and molnupiravir.
2. A preventive and / or therapeutic drug for SARS-CoV-2 infection comprising a combination of ivermectin and molnupiravir.
3. A preventive and / or therapeutic drug for COVID-19 comprising a combination of ivermectin and molnupiravir.
Citation Information
Patent Citations
JP5422302011A
